Actuate Therapeutics (ACTU) has filed for up to 2,777,778 share offering by selling stockholders.

Elraglusib is a Class-LeadingGSK-3β Inhibitor with a Novel, Multimodal Mechanism of Action in Multiple Refractory Cancer Trials Orphan Drug Designation in Soft Tissue Sarcomas Expands Company’s ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Actuate Therapeutics has won Food and Drug Administration orphan-drug designation for its lead investigational drug product in a group of rare cancerous tumors. Actuate on Wednesday said the ...

By Zoë Hopkins Once she was cast out of the United States. Today, her art and activism are front and center at an exhilarating Brooklyn Museum retrospective. By Siddhartha Mitter Axel Rüger ...

11, 2024 (GLOBE NEWSWIRE) -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company, focused on developing therapies for the treatment of ...

Actuate is a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers, including pancreatic cancer and Ewing sarcoma.

CHICAGO and FORT WORTH, Texas - Actuate Therapeutics, Inc. (NASDAQ: ACTU), a clinical-stage biopharmaceutical company, has announced the U.S. Food and Drug Administration (FDA) granted Orphan Drug ...

No matter how powerful generative AI becomes, writer Ted Chiang says it will never create true art. Chiang is one of the most admired science-fiction authors writing today, best known for the ...